Efpeglenatide
As of the edition of 20 October 2026, Efpeglenatide is a protein: in active development; acts on GLP1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Protein
- Registered trials
- 12, 4 stopped early
- Disease areas
- Nutrition and metabolism; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Efpeglenatide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 7 | 2 | 1 | 4 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hanmi Pharmaceutical | Lead sponsor of trials | 2010 to now |
| Sanofi | Lead sponsor of trials | 2018 to now |